Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Small-molecule degraders for oncogenic KRASG12C and pan-KRAS mutations.

Nature communications - 26 Mar 2026

Deng Jianxiong, Shen Shujun, Huang Lei, Xu Fang, Huang Weizhen, Huang Chaoming, Zhang Zhang, Liu Tongzheng, Tan Yi, Li Zhengqiu

Abstract excerpt

KRAS, a frequently mutated oncogene, has been challenging to target therapeutically. Although covalent inhibitors like sotorasib against KRASG12C have been developed, their efficacy is often limited by acquired resistance. Targeted protein degradation offers a potential solution but has largely relied on large PROTAC molecules. Here, we report DJX-A-KM, a small-molecule degrader of KRASG12C, designed by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to F-Box Proteins

Share to Proteasome Endopeptidase Complex

Share to Proteolysis

Share to Proto-Oncogene Proteins p21(ras)

Share to Small Molecule Libraries

Share to Ubiquitin-Protein Ligases

Source

Open in PubMed Open full text

Identifiers

PMID: 41888140
DOI: 10.1038/s41467-026-71093-9
PMCID: PMC13183928

Genes

KRAS
FBXO28

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Small-molecule degraders for oncogenic KRASG12C and pan-KRAS mutations.PMID 41888140Read ↗

Targeting cancer with small molecule pan-KRAS degradersSemantic proximity Read ↗

Targeting cancer with small-molecule pan-KRAS degraders.Semantic proximity Read ↗

Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC.Semantic proximity Read ↗

Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRASG12D.Semantic proximity Read ↗

Research progress of direct and indirect KRAS-targeting protein degraders in KRAS-mutant cancers.Semantic proximity Read ↗

Discovery of highly potent and selective KRASG12C degraders by VHL-recruiting PROTACs for the treatment of tumors with KRASG12C-Mutation.Semantic proximity Read ↗

A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS.Semantic proximity Read ↗

From KRASG12D to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design.Semantic proximity Read ↗

Stopping the beating heart of cancer: KRAS reviewed.Semantic proximity Read ↗

A pan-KRAS degrader for the treatment of KRAS-mutant cancersSemantic proximity Read ↗

Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors.Semantic proximity Read ↗

A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRASG12C Inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.